A compelling new study is building on a growing body of evidence showing a common exercise supplement used to build muscle ...

Inc. stock despite strong Phase 2b data. Click for my updated look at MNMD stock and its market opportunities.

NeuroStar is committed to advancing the body of scientific research and elevating mental health treatment through robust research and data-driven innovation,” stated Keith J. Sullivan, President and ...

(HealthDay News) — Preventive psychological interventions may be effective for adults with subthreshold depressive symptoms, according to a review published online in the December issue of The Lancet ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few years now.

A new study from the Texas A&M University School of Public Health provides additional evidence that meditation using ...

Neurocrine Biosciences advances Phase 3 plans for osavampator after achieving Phase 2 success in major depressive disorder, amending its Takeda deal.

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance ...

Takeda is taking back the home license for a phase 3-stage depression drug as part of an amendment to its multi-asset ...

The scientific literature has highlighted the role of inflammation in major depressive disorder (MDD), permeating several states of the disease. In chronic ...

First, the stigma surrounding mental health is a significant barrier that needs to be tackled at the individual level ...